YGION Biomedical GmbH, a company dedicated to developing individualized neoantigen-based cancer vaccines, has announced the completion of a EUR 15 million Series A financing round from an Austrian private trust. 

The funds will be used to further develop YGION's innovative YGNITE™ technology platform and advance their lead program, YG-01, into preclinical and clinical stages.

Founded in 2022, YGION boasts a high-profile team of experienced biotech veterans and entrepreneurs focused on creating 'plug-and-play' cancer vaccines. Utilizing a proprietary suite of technologies, YGION aims to identify, produce, and deliver relevant peptide neoepitopes, leading to safe, potent, and precisely targeted activation of patients' immune systems.

"We are on the cusp of a breakthrough in individualized cancer treatments," said Dr. Wolfgang Fischl, Chief Executive Officer of YGION. "This financing is truly exciting for YGION as we see it as a strong validation of our unique approach, and we are grateful for the support of our investors enabling us to take a significant step towards clinical validation of our technology. With the continued demonstration of the efficacy of our approach, we are open to additional investors and collaborators interested in our ground-breaking approach," added Fischl.

Dr. Geert Mudde, Chief Technology Officer of YGION, said, "We are confident that with our technology, we can realize the promise of simple, safe, and effective cancer vaccines. Our YGNITE™ platform gives us the unique ability to identify, select, and synthesize relevant neoantigens, and combined with our CARGONAUT™ immune-modulating carrier induces a powerful cell-mediated tumor-specific response that targets and eliminates malignant cells with unmatched safety."

YGION's lead program, YG-01, is currently in preclinical development, with the new funding poised to propel it towards clinical trials.